Article
CFTR deltaF508 carrier status, risk of breast cancer before the age of 40 and histological grading in a population-based case-control study.
International journal of cancer - 23 Oct 1998
Southey M C, Batten L, Andersen C R, McCredie M R, Giles G G, Dite G, Hopper J L, Venter D J
Abstract excerpt
There has been recent interest in the risk of various cancers in cystic fibrosis (CF) patients and carriers of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. It has been proposed that a CFTR mutation may protect against breast cancer, based on evidence that elevated extracellular adenosine triphosphate (ATP) is known to inhibit breast cancer cell line growth and that CFTR pumps ATP out of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.